Novocure (NVCR) Reports Phase 3 METIS Trial Met Primary Endpoint
Go back to Novocure (NVCR) Reports Phase 3 METIS Trial Met Primary Endpoint| (NASDAQ: NVCR) | Delayed: 13.11 -1.06 (7.48%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $14.17 | 52 Week High | $28.95 | |||
| Open | $12.60 | 52 Week Low | $5.95 | |||
| Day High | $13.85 | P/E | N/A | |||
| Day Low | $11.85 | EPS | $0.00 | |||
| Volume | 5,955,757 | |||||



